Magenta Therapeutics, Inc.

NasdaqCM:MGTA Stock Report

Market Cap: US$42.2m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Magenta Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Magenta Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Dec 10

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 25

Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate

Goldman Sachs has downgraded Magenta Therapeutics (NASDAQ:MGTA) from buy to neutral due to a lack of proof-of-concept generating events for one of its lead programs, MGTA-117. The firm kept its $2 price target (~3% upside based on Wednesday's close). Shares are down 7% in Thursday morning trading. MGTA-117, an antibody drug conjugate, is in phase 1 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes (MDS). Data is expected in Q4. "Absent greater clarity on the MGTA-117 dose to be pursued in [hematopoietic stem cell transplantation] and a defined clinical trial path in the transplant setting (FDA interactions expected by YE22/early-23), we are moving to the sidelines," analyst Madhu Kumar wrote. Seeking Alpha's Quant Rating views Magenta (MGTA) as a buy with high marks for valuations, momentum and revisions.
Analysis Article • Jul 13

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 12

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 16

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Aug 26

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 09

We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 17

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...
Analysis Article • Jan 23

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 01

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

A look at the shareholders of Magenta Therapeutics, Inc. (NASDAQ:MGTA) can tell us which group is most powerful. Large...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Magenta Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:MGTA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2023N/A-69-70-73N/A
3/31/2023N/A-83-83-83N/A
12/31/2022N/A-76-67-67N/A
9/30/2022N/A-76-66-66N/A
6/30/2022N/A-77-68-66N/A
3/31/2022N/A-77-64-62N/A
12/31/2021N/A-71-61-60N/A
9/30/2021N/A-70-59-58N/A
6/30/2021N/A-70-58-58N/A
3/31/2021N/A-72-64-64N/A
12/31/2020N/A-75-64-64N/A
9/30/2020N/A-80-66-66N/A
6/30/2020N/A-83-64-63N/A
3/31/2020N/A-82-61-59N/A
12/31/2019N/A-77-60-57N/A
9/30/2019N/A-70-61-54N/A
6/30/2019N/A-65-62-53N/A
3/31/2019N/A-61-56-47N/A
12/31/2018N/A-58-50-42N/A
9/30/2018N/A-49-41-37N/A
6/30/2018N/A-40-34-32N/A
3/31/2018N/A-42-30-28N/A
12/31/2017N/A-36-24-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MGTA's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if MGTA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if MGTA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MGTA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MGTA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MGTA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/11 01:56
End of Day Share Price 2023/09/11 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Magenta Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Yun ZhongBTIG
Edward WhiteH.C. Wainwright & Co.